TABLE 4.

Sociodemographic, Comorbidity, and Clinical Characteristics Associated With Breast Cancer-specific Survival

Characteristic	UVA—HR (95% CI)	P	MVA—HR (95% CI)	P
ADI
1–3	Reference	0.033	Reference	0.040
4–10	1.43 (1.03–1.99)		1.56 (1.02–2.38)
Age
<49	Reference	0.3
50–69	1.24 (0.84–1.82)
>70	1.42 (0.89–2.28)
Race
White	Reference	0.025	Reference	0.5
Black	1.80 (1.22–2.65)		1.07 (0.63–1.82)
Asian	1.05 (0.6–1.83)		0.98 (0.48–2.02)
Other	1.45 (0.89–2.36)		1.56 (0.87–2.79)
Hispanic ethnicity
No	Reference	0.14
Yes	1.43 (0.90–2.27)
Insurance
Private or Medicare	Reference	<0.001	Reference	0.008
Medicaid	2.10 (1.47–3.00)		1.91 (1.21–3.01)
BMI
Normal	Reference	0.5
Overweight	1.07 (0.71–1.61)
Obese	1.26 (0.86–1.86)
Alcohol use
Never	Reference	0.3
Socially	0.78 (0.55–1.10)
Frequently	1.03 (0.45–2.35)
Smoking
No	Reference	0.2
Yes	0.8 (0.57–1.12)
Clinical stage
1	Reference	<0.001	Reference	<0.001
2	2.96 (2.01–4.38)		2.16 (1.36–3.44)
3	9.51 (6.07–14.9)		5.88 (3.24–10.7)
Tumor differentiation
Well or moderately	Reference	<0.001	Reference	0.006
Poorly	3.98 (2.60–6.07)		2.03 (1.22–3.37)
Tumor subtype
ER+/HER2−	Reference	<0.001	Reference	<0.001
ER+/HER2+	0.90 (0.41–1.97)		0.59 (0.23–1.51)
ER−/HER2+	0.88 (0.32–2.43)		0.20 (0.003–1.56)
ER−/HER2−	5.17 (3.62–7.38)		2.53 (1.26–5.08)
Chemotherapy
No	Reference	<0.001	Reference	0.113
Yes	1.95 (1.39–2.75)		0.67 (0.41–1.10)
Radiation
No	Reference	<0.001	Reference	0.5
Yes	2.23 (1.46–3.40)		1.16 (0.71–1.90)
Endocrine therapy
No	Reference	<0.001	Reference	0.8
Yes	0.26 (0.19–0.36)		0.93 (0.47–1.83)

BMI indicates body mass index; MVA, multivariable; UVA, univariable.